An Independent Data Monitoring Committee Recommends Alterity Therapeutics' ATH434-201 Phase 2 Study In Early-stage Multiple System Atrophy, Continue As Planned; The Trial Will Complete Enrollment In Q3 2023, With Top-line Data Expected By The End Of 2024
Portfolio Pulse from Benzinga Newsdesk
An Independent Data Monitoring Committee has recommended that Alterity Therapeutics' ATH434-201 Phase 2 study in early-stage Multiple System Atrophy should continue as planned. The trial is expected to complete enrollment in Q3 2023, with top-line data expected by the end of 2024.
July 26, 2023 | 10:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The continuation of Alterity Therapeutics' ATH434-201 Phase 2 study could potentially boost investor confidence in the company's research and development capabilities.
The continuation of the ATH434-201 Phase 2 study indicates that the Independent Data Monitoring Committee sees potential in the trial. This could boost investor confidence in Alterity Therapeutics' research and development capabilities, potentially leading to a short-term increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100